Skip to search formSkip to main contentSkip to account menu

faldaprevir

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Effect of Steady‐State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open‐Label, Fixed‐Sequence Crossover Study
Faldaprevir (FDV) is a potent, orally administered inhibitor of hepatitis C virus protease. It inhibits multiple cytochrome P‐450… 
2015
2015
Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in…
ABSTRACT Analysis of data pooled from multiple phase 2 (SILEN-C1 to 3) and phase 3 studies (STARTVerso1 to 4) of the hepatitis C… 
Review
2015
Review
2015
Faldaprevir for the Treatment of Hepatitis C
The current treatments for chronic hepatitis C virus (HCV) genotype 1 infection are combinations of direct-acting antivirals, and… 
2015
2015
STARTVerso 1 : A randomized trial of faldaprevir plus pegylated interferon / ribavirin for chronic HCV genotype-1 infection q
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection Peter… 
2014
2014
Enzyme-Transporter Interplay in the Formation and Clearance of Abundant Metabolites of Faldaprevir Found in Excreta but not in Circulation
Faldaprevir is a hepatitis C virus protease inhibitor that effectively reduces viral load in patients. Since faldaprevir exhibits… 
Review
2014
Review
2014
Interferon-Free Strategies without a Nucleoside/Nucleotide Analogue
Abstract The identification of viral and host factors involved in hepatitis C virus (HCV) replication was a key prerequisite for… 
2014
2014
Generating an In Vitro–In Vivo Correlation for Metabolism and Liver Enrichment of a Hepatitis C Virus Drug, Faldaprevir, Using a Rat Hepatocyte Model (HepatoPac)
Hepatocytes provide an integrated model to study drug metabolism and disposition. As a result of a loss of polarity or a… 
2014
2014
P742 THE PHARMACOKINETICS OF GS-5816, A PAN-GENOTYPIC HCV NS5A INHIBITOR, IN HCV-UNINFECTED SUBJECTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT
2014
2014
Current race in the development of DAAs (direct-acting antivirals) against HCV.
Review
2013
Review
2013
Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?
The current standard of care (SOC) for patients with chronic HCV genotype 1 is a combination of either boceprevir or telaprevir… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)